The synthetic FXR agonist WAY-362450 reduced MCP-1 expression and inflammatory cell infiltration in the liver of mice put on methionine-choline deficient (MCD) diet, which induces NASH. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.